Global contract packaging organisation, Tjoapack, has signed a five-year agreement with Photocure for the packaging of its proprietary bladder cancer detection products.
Hexvix®/Cysview® is a drug that is selectively taken up by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLCTM with Hexvix/Cysview improves the detection of tumours and leads to more complete resection, less residual tumours and better management decisions.
The contract will see Tjoapack perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.
Dexter Tjoa, Director Corporate Strategy at Tjoapack said:
“Were delighted to be working with a company like Photocure whos technology can make such a difference to patients. Photocure has a global customer base, which comes with many potential challenges.”
During the project, Tjoapack will be working with semi-finished stock stored at its facility, only finalising and assembling kits when orders come in.
Gry Stensrud, VP of Technical Development & Operations, at Photocure said:
“Photocure delivers transformative solutions to improve the lives of bladder cancer patients. This is very much in line with Tjoapacks ethos which was a big decision-making factor for us when choosing a partner.”
Founded in 1989, Tjoapack is an independent contract packager of medicines servicing clients across five continents and 42 countries. The CPO specialises in primary packaging for solid dosage forms, secondary packaging, unit dose packaging and serialisation. The company now has a total of 19 packaging lines, including blisters, wallets and bottles, as well as developing bespoke solutions for specialist projects.